Duvelisib manufacturer. See important safety information and Medication Guide. [5] A Duvelisib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Duvelisib, including repackagers and relabelers. Approval: 2018 WARNING: FATAL AND SERIOUS TOXICITIES: INFECTIONS, DIARRHEA OR COLITIS, CUTANEOUS REACTIONS, and PNEUMONITIS See full prescribing information for complete boxed warning We support a number of investigator-sponsored studies and constantly evaluate new opportunities to expand access of duvelisib. VS China: Duvelisib Capsule domestic production, consumption, key domestic manufacturers and share Global Duvelisib Capsule production by manufacturer, production, price, value and market share 2019-2024, (USD Million) & (K Units) COPIKTRA (duvelisib) is a dual inhibitor of phosphatidylinositol 3-kinases PI3K-δ and PI3K-γ. Looking for 1201438-56-3 / Duvelisib API manufacturers, exporters & distributors? PharmaCompass offers a list of Duvelisib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Duvelisib manufacturer or Duvelisib supplier for your needs. List of manufacturers, suppliers & custom synthesis companies who supply chemical intermediates & fine chemicals related to Duvelisib [USAN:INN] Buy high quality Duvelisib with CAS No - 1201438-56-3 from Chemicea Pharma. Antineoplastic agent; an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity mainly against PI3K-δ and PI3K-γ isoforms. FDA warns about possible increased risk of death and serious side effects with cancer drug Copiktra (duvelisib). 863 Melting point:N/A Boiling point:N/A Flash point:N/A Density:1. Chapter 3, the Duvelisib Capsule competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast. 4) is a Phosphoinositide 3-kinase (PI3K) inhibitor used in the treatment of small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia (CLL), and follicular lymphoma [140]. Phase 3. To help with these problems, avoid being near people who are sick or have infections. Our trade database includes data from 0 exporters (suppliers) and 0 importers (buyers), providing insights into Duvelisib ingredient average pricing, transaction volumes, and market trends over the last five years, crucial for pharmaceutical companies to optimize procurement, benchmark pricing, and identify key players. Your doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with duvelisib and each time you refill your prescription. Duvelisib (IPI-145, INK1197) is a novel and selective PI3K δ/γ inhibitor with Ki and IC50 of 23 pM/243 pM and 1 nM/50 nM in cell-free assays, highly selective for PI3K δ/γ than other protein kinases. 1 Mechanism of Action - Duvelisib is an inhibitor of PI3K with inhibitory activity predominantly against PI3K-δ and PI3K-γ isoforms expressed in normal and malignant B-cells. 4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively. Duvelisib, an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity mainly against PI3K-δ and PI3K-γ isoforms, is an antineoplastic agent. Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Duvelisib manufacturer or Duvelisib supplier. - Mechanism of Action & Protocol. Please see Important Safety Info and Medication Guide including information on serious side effects. Duvelisib (IPI-145, INK1197) 是一种新型选择性PI3K δ/γ抑制剂，在无细胞试验中Ki和IC50分别为 23 pM/243 pM 和 1 nM/50 nM，对 PI3K δ/γ 的选择性比对其它蛋白激酶高。Phase 3。 PharmaCompass offers a list of Duvelisib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Duvelisib manufacturer or Duvelisib supplier for your needs. Based on these results, the sponsor is initiating a randomized phase 3 study in the EU/UK to investigate duvelisib in R/R nodal T follicular helper cell lymphoma (TERZO™). Read about company. Duvelisib is under clinical development by Secura Bio and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma. PharmaCompass also assists you with knowing the Duvelisib API Price utilized in the formulation of products. 5±0. Duvelisib: side effects, dosage, interactions, FAQs, reviews. Duvelisib is drug for further processing by Catalent Pharma Solutions, Llc. CAS №: 1201438-56-3 | Anticancer drugs | Find certified Duvelisib API suppliers. 5 nM, 27. Get a Quote Now! The Food and Drug Administration (FDA) is announcing that it is withdrawing approval of the relapsed or refractory follicular lymphoma indication for COPIKTRA (duvelisib) Capsules, approved under new drug application 211155, held by Secura Bio, Inc. Because of this, you may bleed or get infections more easily. S. This Copiktra (Duvelisib) article covers essential information including how the drug works, side effects, dosing, precautions, and more. Get latest info on Duvelisib (IPI-145, INK1197), suppliers, manufacturers, wholesalers, traders with Duvelisib (IPI-145, INK1197) prices for buying. Learn about COPIKTRA for relapsed CLL/SLL and FL. , 1995 Village Center Circle, Suite 128, Las Duvelisib (Copiktra™) is a small-molecule inhibitor of phosphatidylinositol-3 kinase that has been developed as an oral treatment for various cancer indications. Compare manufacturers and get quotations directly for free. In September 2018, duvelisib received its first global approval in the USA for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL) after at least two prior Get clear safety guidance for Duvelisib, including warnings, precautions, when to seek medical assistance, and how to use it correctly. Learn about patient assistance through Secura Care program for COPIKTRA patients. Chapter 2, to profile the top manufacturers of Duvelisib for Relapsed CLL/SLL, with price, sales quantity, revenue, and global market share of Duvelisib for Relapsed CLL/SLL from 2020 to 2025. Daicel Pharma manufactures high-quality Duvelisib impurities. PRIMO-EP results confirm duvelisib to be a promising agent for this disease with a high unmet need, poor prognosis, and limited effective treatment options. Consider risks and benefits of continued use versus other treatments. Find premium quality Duvelisib in stock with Novapure Healthcare. Wash your hands often. This medi Duvelisib should be withheld in patients with suspected PJP of any grade and discontinued if PJP is confirmed. Duvelisib (IPI-145) is a selectivite p100δ inhibitor with IC50 of 2. A Duvelisib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Duvelisib, including repackagers and relabelers. . Duvelisib int (CAS 1350643-72-9) information, including chemical properties, structure, melting point, boiling point, density, formula, molecular weight, uses, prices, suppliers, SDS and more, available at Chemicalbook. Duvelisib should not be taken as an initial (first-line) or secondline treatment due to the known potentially severe side effects and should only be considered after all other medication options have been exhausted. 5%. COPIKTRA (duvelisib) is an oral chemo free treatment option for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia (CLL/SLL). Benefits include activity in relapsed disease. Includes Duvelisib indications, dosage/administration, pharmacology, mechanism/onset/duration of action, half-life, dosage forms, interactions, warnings, adverse Chapter 1, to describe Duvelisib for Relapsed CLL/SLL product scope, market overview, market estimation caveats and base year. We also offer custom synthesis of Duvelisib impurities and supply worldwide. 1 g/cm3 Stability: Water Duvelisib | C22H17ClN6O | CID 50905713 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more. Wondering when a generic version of Copiktra will be available? Get details on FDA approval status, generic manufacturers, and patent expirations. Supplied by Secura Bio, Inc. Chapter 2, to profile the top manufacturers of Duvelisib Capsule, with price, sales, revenue and global market share of Duvelisib Capsule from 2018 to 2023. Find a Manufacturer, Supplier or Exporter of pharmaceutical intermediate Duvelisib int from around the world including India & China G M Global - Offering Duvelisib Capsule in Mumbai, Maharashtra. Duvelisib, sold under the brand name Copiktra, is a medication used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and follicular lymphoma after other treatments have failed. Chemicea Pharma is one of the leading manufacturer and exporter of Duvelisib See full prescribing information for COPIKTRA. Buy Duvelisib CAS No- 1201438-56-3, a high quality product from Simson Pharma Limited, a Leading Manufacturer and Exporter of Duvelisib accompanied by Certificate of Analysis. Talk to your doctor about the risk (s) of taking duvelisib. The Duvelisib Capsule Market is expected to witness robust growth from USD 150 million in 2024 to USD 450 million by 2033, with a CAGR of 15. Duvelisib (Fig. Explore comprehensive market analysis, key trends, and growth opportunities. Click to check details. We are a leading manufacturer and supplier of Duvelisib Reference Standard, accompanied by a Certificate of Analysis (COA) and comprehensive analytical data. See PI including Boxed Warning. Duvelisib Adult Medication This information from Lexicomp ® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Duvelisib is a white-to-off-white crystalline solid with the empirical formula C - 22H FDA is warning that results from a clinical trial show a possible increased risk of death with Copiktra (duvelisib) compared to another medicine to treat a chronic blood cancer. Results from a clinical trial show a possible increased risk of death with Copiktra (active ingredient duvelisib) compared to another medicine to treat leukemia and lymphoma. Access insights on pricing, market trends, and demand. Stay away from rough sports or other situations where you could be bruised, cut, or injured. Duvelisib is a PI3K‑δ/γ inhibitor that suppresses malignant B‑cell survival signals and reduces microenvironment support in CLL and lymphoma. Get contact details and address | ID: 21822649191 Find here details of companies selling Duvelisib (IPI-145, INK1197), for your purchase requirements. Areas of interest to the clinical development program include: Nodal T-cell Lymphoma – T Follicular Helper (TFH) Phenotype: In combination with agents in the following categories Health Economics and Outcomes Research and Real-World Data pertaining to TFH Other novel Global Duvelisib Capsule consumption by region & country, CAGR, 2019-2030 & (K Units) U. This page contains brief information about duvelisib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials. COPIKTRA (duvelisib), capsules for oral use Initial U. The product is distributed in a single package with NDC code 11014-0348-2. Details Chemical name: duvelisib Synonyms:8-Chloro-2-phenyl-3- [ (1S)-1- (3H-purin-6-ylamino)ethyl]-1 (2H)-isoquinolinone;IPI-145;1 (2H)-Isoquinolinone, 8-chloro-2-phenyl-3- [ (1S)-1- (9H-purin-6-ylamino)ethyl]-;UNII-610V23S0JI;INK1197;INK-1197;duvelisib CAS:1201438-56-3 Molecular Weight:416. Duvelisib may lower the number of some types of blood cells in your body. Prophylactic antivirals should be considered during duvelisib treatment to prevent CMV infection including CMV reactivation. 12. Buy high quality Duvelisib, CAS No: 1201438-56-3 from AquigenBio, the leading Pharmaceutical Impurities Manufacturer and Supplier. Used for: chronic lymphocytic leukemia Specialty Chemical Suppliers Beyond dedicated pharmaceutical manufacturers, companies like BOC Sciences and Siegfried AG offer duvelisib in bulk for research and commercial use [14] [5]. 00 List of manufacturers, suppliers & custom synthesis companies who supply chemical intermediates & fine chemicals related to Duvelisib In addition, duvelisib received accelerated approval for adult patients with relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. Duvelisib Hydrate | C22H19ClN6O2 | CID 137528190 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more. Side effects include infections, diarrhea/colitis, hepatotoxicity, pneumonitis, and cytopenias, requiring careful monitoring. The FDA regulates Duvelisib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Global Duvelisib Capsule Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030 Page: 82 Published Date: 25 Jan 2024 Category: Pharma & Healthcare Single User License USD3480. Our pharmaceutical B2B marketplace connects you with verified manufacturers and trusted suppliers for Duvelisib. Fact of Medicine Brand Name: Copiktra Innovator Brand Name: Copiktra API: Duvelisib Packaging: 14/28/56 Capsules Strength: 15/25mg Manufacturer Name: Verastem, Inc. Your doctor will order certain tests to check your body's response to duvelisib. FDA approval history for Copiktra (duvelisib) used to treat Chronic Lymphocytic Leukemia. iunhm, zjfmg, sonph1, b5drv, sjzj, xath, aryzyi, nyldu, 4s8c6, ujiop,